The integration of AI and cloud technologies is transforming pharmaceutical manufacturing regulations, focusing on safety, efficiency, and global harmonization.

The psoriasis market is estimated at $30 Billion by 2030 and has shifted significantly to oral drugs Ramat Gan, Israel, March 24, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) ...

"We are excited to initiate the Phase 3 study and we believe that Piclidenoson's oral dosage and excellent safety record, ...

Biosimilars are essential healthcare equalizers, but their regulation is overly complicated due to lobbying by makers of ...

Although the regulatory landscape for advanced therapy medicinal products (ATMPs) is rapidly evolving, varying regulatory ...

Namodenoson, has been also granted Orphan Drug Designation by the FDA for pancreatic cancer. The designation as an orphan drug will provide, among others, potential for market exclusivity for seven ...

Q4 2024 Earnings Call Transcript March 17, 2025 Protalix BioTherapeutics, Inc. beats earnings expectations. Reported EPS is $0.09, expectations were $0.07. Operator: Good morning, ladies and gentlemen ...

Global biosimilar regulatory harmonization will be needed to reduce development costs and improve patient access, despite ...

Cytokinetics is now rapidly moving into commercialization efforts with Aficamten. Read more to see why I rate CYTK stock a ...

The study found that just 20% of trials submitted to both the FDA and European Medicines Agency had matching evidence.

The following is a summary of “Naldemedine Use and Healthcare Resource Utilization in Patients treated with Opioid Analgesics for Chronic Non-Cancer Pain: Results of a Real-world Study in the USA,” ...

The following is a summary of “Digitally supported physical activity counselling for people with chronic back pain: a randomised controlled parallel feasibility study,” published in the February 2025 ...